Patents Issued in May 9, 2024
  • TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS
    Publication number: 20240148732
    Abstract: The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for treating diseases, such as cancer, autoimmune disorders, and inflammatory disorders.
    Type: Application
    Filed: January 25, 2022
    Publication date: May 9, 2024
    Inventors: Shulu FENG, Morgan LAWRENZ, Jiaye GUO, Goran KRILOV, Andrew PLACZEK, Zhe NIE, Lynnie TRZOSS, Haifeng TANG, Pieter Harm BOS, Michael TRZOSS, Shelby ELLERY
  • COMBINATION THERAPY
    Publication number: 20240148733
    Abstract: Provided herein is a combination, comprising: (i) one or more YAP/TAZ-TEAD inhibitors; and (ii) one or more KRAS inhibitors, such as the specific YAP/TAZ-TEAD inhibitors and KRAS inhibitors described herein. Also provided herein are methods of modulating or inhibiting KRAS activity in a cell, comprising administering to the cell an effective amount of such combinations. Also provided herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of such combinations.
    Type: Application
    Filed: November 15, 2023
    Publication date: May 9, 2024
    Inventors: Anwesha DEY, Marie EVANGELISTA
  • SELECTIVE INHIBITOR OF EXON 20 INSERTION MUTANT EGFR
    Publication number: 20240148734
    Abstract: An antitumor agent comprising a compound selected from the group consisting of Compounds A to D described in the specification, or a salt thereof, for treating a malignant tumor patient expressing EGFR having exon 20 insertion mutation.
    Type: Application
    Filed: November 17, 2023
    Publication date: May 9, 2024
    Applicant: Taiho Pharmaceutical Co., Ltd.
    Inventors: Kazutaka Miyadera, Yoshimi Aoyagi, Shinichi Hasako
  • METHODS OF TREATING HEART FAILURE WITH VIBEGRON
    Publication number: 20240148735
    Abstract: The present disclosure provides methods of treating or preventing heart failure and/or one or more symptoms thereof, the methods comprising administering to a subject in need thereof a therapeutically effective amount of vibegron.
    Type: Application
    Filed: February 16, 2022
    Publication date: May 9, 2024
    Inventor: Jihao ZHOU
  • COMBINATION DRUG FOR TREATING RENAL CANCER AND POTENTIATOR FOR THERAPEUTIC EFFECTS OF TYROSINE KINASE INHIBITOR
    Publication number: 20240148736
    Abstract: The present invention relates a combination drug for treating a renal cancer and a potentiator for therapeutic effects of a tyrosine kinase inhibitor. The combination drug includes a combination of a tyrosine kinase inhibitor, and a dipeptidyl peptidase-4 inhibitor. The potentiator includes a dipeptidyl peptidase-4 inhibitor. The potentiator enhances therapeutic effects of a tyrosine kinase inhibitor on a renal cancer.
    Type: Application
    Filed: December 13, 2021
    Publication date: May 9, 2024
    Inventors: Satoshi INOUE, Kazuhiro IKEDA, Kuniko INOUE, Shuhei KAMADA, Satoru KAWAKAMI
  • TREATMENT FOR DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH AN ORAL ANTIDIABETIC DRUG
    Publication number: 20240148737
    Abstract: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients with insufficient glycemic control despite a therapy with an oral and/or a non-oral antidiabetic drug.
    Type: Application
    Filed: January 16, 2024
    Publication date: May 9, 2024
    Inventors: Eva Ulrike GRAEFE-MODY, Thomas KLEIN, Michael MARK, Hans-Juergen WOERLE
  • METHOD OF INCREASING THE POPULATION OF BLAUTIA SPP. IN THE GUT MICROBIOME
    Publication number: 20240148738
    Abstract: The direct delivery of antioxidant compounds (Vitamin B2, Vitamin C, beta-carotene, and Vitamin E) to the large intestine results in an increase in the population of Blautia spp. in the gut. People with lower amounts of Blautia spp. often experience obesity, insulin resistance and chronic inflammation, major depressive disorder as well as other conditions which can be helped by increasing their population of Blautia. An increase in the population of Blautia also increases the amount of beneficial short chain fatty acids in the intestine as well.
    Type: Application
    Filed: March 3, 2022
    Publication date: May 9, 2024
    Inventors: Thanh-Van PHAM, Ateequr REHMAN, Robert STEINERT, Wilbert SYBESMA
  • METHOD OF DECREASING THE POPULATION OF FUSOBACTERIA IN THE GUT MICROBIOME
    Publication number: 20240148739
    Abstract: Delivery of antioxidants (Vitamin C, Vitamin E, riboflavin, and beta-carotene) directly to the large intestine were seen to decrease the population of Fusobacterium in the gut microbiome. An increased population of these bacteria is associated with Fusobacterium bacteremia as a co-morbidity with any one of: malignancy, dementia, chronic obstructive lung disease, diabetes, heart disease, alcoholism, disease(s) requiring dialysis, and stroke; colorectal cancer; digestive diseases including Ulcerative colitis; Crohn's disease; and/or Pediatric or adult inflammatory bowel disease; colorectal and other cancers, inflammatory bowel disease, adverse pregnancy-related conditions, and HIV.
    Type: Application
    Filed: March 17, 2022
    Publication date: May 9, 2024
    Inventors: Thanh-Van PHAM, Ateequr REHMAN, Nicole SEIFERT, Robert STEINERT, Wilbert SYBESMA
  • COMBINATION OF AN AHR INHIBITOR WITH A PDX INHIBITOR OR DOXORUBICINE
    Publication number: 20240148740
    Abstract: The present invention provides AHR inhibitors, and methods of use thereof.
    Type: Application
    Filed: October 28, 2021
    Publication date: May 9, 2024
    Inventors: Alfredo C. CASTRO, Xiaoyan Michelle ZHANG, Jason SAGER, Karen J. MCGOVERN
  • FORMULATION FOR ORAL ADMINISTRATION, COMPRISING TRIAZINE DERIVATIVE
    Publication number: 20240148741
    Abstract: The present invention provides a formulation for oral administration, comprising a triazine derivative having virus proliferation inhibitory action.
    Type: Application
    Filed: November 22, 2022
    Publication date: May 9, 2024
    Applicant: Shionogi & Co., Ltd.
    Inventors: Masato GOMI, Kensuke HORIUCHI, Masayuki MORIMOTO, Keisuke TAKAGAKI
  • METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOF
    Publication number: 20240148742
    Abstract: The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TR? mutation.
    Type: Application
    Filed: December 22, 2023
    Publication date: May 9, 2024
    Inventors: D. Keith HESTER, II, Robert J. DUGUID, Martha J. KELLY, Anna CHASNOFF, Gang DONG, Edwin L. CROW, Lianhe SHU, Ping WANG, Duk Soon CHOI
  • USES OF MELANOCORTIN-4 RECEPTOR AGONIST
    Publication number: 20240148743
    Abstract: The present invention relates to uses of a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof for the purpose of preventing or treating rare genetic obesity diseases, particularly rare genetic obesity diseases associated with a damaged melanocortin-4 receptor (MC4R) pathway.
    Type: Application
    Filed: January 20, 2022
    Publication date: May 9, 2024
    Applicant: LG CHEM, LTD.
    Inventors: Hee Dong PARK, Su Jin YEO, Hye Won AHN
  • SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES
    Publication number: 20240148744
    Abstract: Provided herein are Sulfonamide compounds of Formula I: and pharmaceutically acceptable salts, tautomers, isotopologues, and stereoisomers thereof, wherein R1, R2, R, A, m, n, and p are as defined herein, compositions comprising an effective amount of a Sulfonamide Compound, and methods for treating or preventing animal and human filarial worm infections and diseases.
    Type: Application
    Filed: February 8, 2022
    Publication date: May 9, 2024
    Inventors: Natalie Hawryluk, Graham Kyne, Sanjay MENON, Matthew Bedore
  • COMPOUNDS FOR USE IN PROGRESSIVE MULTIPLE SCLEROSIS
    Publication number: 20240148745
    Abstract: The present invention provides compounds able to induce neuroprotection of damaged neurons and boost the remyelination potential of oligodendrocytes. The compounds have been identified through methods of pharmacological screening of a small molecule library consisting of known pharmacologically active compounds and approved drugs. The screening method is also included in the invention.
    Type: Application
    Filed: March 9, 2022
    Publication date: May 9, 2024
    Applicants: FONDAZIONE CENTRO SAN RAFFAELE, INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, SORBONNE UNIVERSITE, WESTFÄLISCHE WILHELMS-UNIVERSITÄT MÜNSTER, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, HEINRICH HEINE UNIVERSITY DÜSSELDORF, UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ, THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY, ISTITUTO SUPERIORE DI SANITÀ, CONSIGLIO NAZIONALE DELLE RICERCHE, IRBM S.P.A.
    Inventors: Gianvito MARTINO, Paola PANINA, Brahim NAIT-OUMESMAR, Anne BARON-VAN EVERCOOREN, Tanja KUHLMANN, Sergio BARANZINI, Norbert GOEBELS, Frauke ZIPP, Nicholas HANUSCHECK, Jack ANTEL, Cristina AGRESTI, Maria Pia ABBRACCHIO, Ivano EBERINI, Chiara PARRAVICINI, Stefania OLLA, Alberto BRESCIANI
  • USE OF COMPOUND OR PHARMACEUTICAL DERIVATIVE THEREOF IN INHIBITING CAMK2G PROTEIN ACTIVITY
    Publication number: 20240148746
    Abstract: A use of a compound or a medicinal derivative thereof in inhibiting calcium/calmodulin-dependent protein kinase type II gamma (CaMK2?) protein activity is provided, and belongs to the technical field of protein inhibitors. Compared with traditional broad-spectrum immunomodulators, the compound has a strong targeting effect, and is more accurate, rapid, effective, safe, and stable. Moreover, the compound has a strong binding force with human-derived CaMK2? protein and mouse-derived CaMK2? protein, and binding constants are KD=2.54×10?5M and KD=6.84×10?5M respectively. Compared with traditional biological inhibitors, the compound has advantages of easy storage, stable activity, small molecular weight, lower production cost and easy absorption.
    Type: Application
    Filed: December 16, 2022
    Publication date: May 9, 2024
    Inventor: Liangdan Sun
  • SMALL MOLECULE ACTIVATORS OF YAP TRANSCRIPTIONAL ACTIVITY FOR REGENERATIVE ORGAN REPAIR
    Publication number: 20240148747
    Abstract: The present disclosure provides compounds, or their tautomers or pharmaceutically acceptable salts thereof, and their pharmaceutical compositions that can selectively activate Yes-associated protein 1 (YAP). YAP activators of the present disclosure are useful in therapies such as wound and organ repair including, for example, treatment of chronic ulcers.
    Type: Application
    Filed: February 11, 2022
    Publication date: May 9, 2024
    Inventors: Michael J. Bollong, Peter G. Schultz, Arnab Chatterjee, Weijun Shen, Elshan Nakath G. Ralalage, Edyta M. Grzelak, Pengyu Yang
  • CHROMIUM CONTAINING COMPOSITIONS FOR IMPROVING HEALTH AND FITNESS
    Publication number: 20240148748
    Abstract: Administration of certain chromium complexes in combination with a starch provide unexpected benefits regarding increasing amino acid absorption, protein synthesis, exercise tolerance, lean muscle mass, skeletal muscle hypertrophy, muscle power, muscle endurance, muscle strength, FSR, and decreasing delayed onset muscle soreness, muscle protein breakdown, and fat mass.
    Type: Application
    Filed: November 16, 2023
    Publication date: May 9, 2024
    Inventor: James R. Komorowski
  • MNTBAP AND M(III)N-SUBSTITUTED PYRIDYLPORPHYRINS(MNPS)FOR USE IN REVERSING SEPSIS-INDUCED MICROGLIAL CELLS ALTERATIONS AND/OR FOR TREATING SEPSIS OR SEPSIS-ASSOCIATED ENCEPHALOPATHY
    Publication number: 20240148749
    Abstract: The invention relates to MnTBAP or Mn(III) substituted pyridylporphyrin (MnP) compounds selected among MnTE-2-pYP5+, MnTEHex-2-Pyp5+ and MnTnBuOE-2-Pyp5+ for use in treating sepsis and/or reversing sepsis-induced microglial cells alteration(s), and/or reversing associated long-term cognitive impairment in a subject diagnosed with sepsis or sepsis-associated encephalopathy (SAE), and/or treating long-term cognitive impairment in a subject suffering from sepsis or sepsis-associated encephalopathy (SAE).
    Type: Application
    Filed: March 18, 2022
    Publication date: May 9, 2024
    Inventors: Miria RICCHETTI, Fabrice CHRETIEN, Franck VERDONK, Laurent Arnaud CHATRE
  • PROSTAMIDE-CONTAINING INTRAOCULAR IMPLANT
    Publication number: 20240148750
    Abstract: Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.
    Type: Application
    Filed: May 15, 2023
    Publication date: May 9, 2024
    Inventors: Patrick M. Hughes, Jie Shen, Michael R. Robinson, David F. Woodward, Robert M. Burk, Hui Li, Jinping Wan, Chandrasekar Durairaj, Gyorgy F. Ambrus, Ke Wu, Danny T. Dinh
  • Identification of oleanolic acid and plant extract for glucose-6-phosphate dehydrogenase-related disorders including Bag3opathy
    Publication number: 20240148751
    Abstract: A method of treating a glucose-6-phosphate dehydrogenase deregulated disorder in a subject in need thereof, the method involving administering a therapeutically effective amount of oleanolic acid or a conjugate salt thereof or prodrug thereof to the subject. The glucose-6-phosphate dehydrogenase deregulated disorder can be BCL2 associated athanogene myofibrillar myopathy, amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, or Alzheimer disease.
    Type: Application
    Filed: October 13, 2022
    Publication date: May 9, 2024
    Inventors: Zhaoxiang BIAN, Tao HUNG, Ling ZHAO, Lidan ZHONG, Chengyuan LIN
  • Canker sore preparation for the treatment of canker sore.
    Publication number: 20240148752
    Abstract: Present invention discloses a topical canker sore preparation, containing combination of hydrocortisone and benzocaine as a novel, and effective active ingredients for the treatment of canker sore.
    Type: Application
    Filed: November 4, 2022
    Publication date: May 9, 2024
    Inventor: SAIF UL ISLAM
  • METHOD AND COMPOSITION FOR REVERSING AND/OR INHIBITING ATHEROSCLEROSIS
    Publication number: 20240148753
    Abstract: The present invention pertains to a method for alleviating atherosclerosis in a subject comprising administrating to said subject a composition or pharmaceutical composition comprising Antcin K.
    Type: Application
    Filed: January 10, 2024
    Publication date: May 9, 2024
    Applicant: ARJIL BIOTECH HOLDING COMPANY LIMITED
    Inventors: Yeh B WU, Jir-Mehng LO, Hui Ju LIANG, Pei-Hsin LIN, Chieh-Hsi WU, Chung-Hsin WU
  • METHODS AND COMPOSITIONS RELATED TO GLUCOCORTICOID RECEPTOR ANTAGONISTS AND BREAST CANCER
    Publication number: 20240148754
    Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.
    Type: Application
    Filed: December 15, 2023
    Publication date: May 9, 2024
    Inventors: Deng Pan, Masha Kocherginsky, Suzanne D. Conzen
  • WATER-BASED PHARMACEUTICAL COMPOSITION CONTAINING URSODEOXYCHOLIC ACID OR SALT THEREOF
    Publication number: 20240148755
    Abstract: The present disclosure provides a pharmaceutical composition comprising ursodeoxycholic acid or a salt thereof, a preservative, and water.
    Type: Application
    Filed: February 14, 2022
    Publication date: May 9, 2024
    Applicant: SANTEN PHARMACEUTICALCO., LTD.
    Inventors: Yoko ENDO, Yusuke OTOMARU, Hitoshi SASAKI, Tatsuya HATA, Tomoko ODA
  • USE OF NEUROACTIVE STEROID FOR TREATMENT OF SEXUAL DYSFUNCTION
    Publication number: 20240148756
    Abstract: This invention relates to methods of treating sexual dysfunction and/or maintaining sexual function in a patient by administering to the patient neuroactive steroids.
    Type: Application
    Filed: January 27, 2022
    Publication date: May 9, 2024
    Inventors: Vijayveer Bonthapally, Ellison Suthoff, Handan Gunduz-Bruce, Ryan Arnold
  • USE OF DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS TO TARGET FERROPTOSIS IN CANCER THERAPY
    Publication number: 20240148757
    Abstract: The present disclosure provides methods for treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a dihydroorotate dehydrogenase (DHODH) inhibitor, wherein the cancer has an altered glutathione peroxidase 4 (GPX4) expression as compared to a control sample. The present disclosure also provides methods of treating a subject with a dihydroorotate dehydrogenase (DHODH) inhibitor where the subject's GPX4 expression is low as compared to a control sample or with a DHODH inhibitor and a ferroptosis inducer where the subject's GPX4 expression is high as compared to a control sample.
    Type: Application
    Filed: March 3, 2022
    Publication date: May 9, 2024
    Inventors: Boyi GAN, Kellen OLSZEWSKI, Chao MAO
  • CONTROLLED RELEASE FORMULATIONS OF HIGHLY LIPOPHILIC PHYSIOLOGICALLY ACTIVE SUBSTANCES
    Publication number: 20240148758
    Abstract: The invention relates to a product for the release of highly lipophilic physiologically active substances, comprising a core and a coating on top of the core, the coating comprising one or more highly lipophilic physiologically active substances, one or more water-soluble film-forming agents and, relative to the weight of all components, not more than 20 wt % of other auxiliary substances.
    Type: Application
    Filed: October 16, 2020
    Publication date: May 9, 2024
    Applicant: ADD Advanced Drug Delivery Technologies Ltd.
    Inventors: Mirko Nowak, Jay Nowak, Annette Grave, Monika Wentzlaff, Sarah Barthold, Christian Geugelin
  • Non-Psychoactive Multi-Cannabinoid And Terpene-Based Therapeutic Compositions And Methods Of Their Administration
    Publication number: 20240148759
    Abstract: A fixed dose combination formulation drug comprised of three cannabinoids, namely cannabidiol, cannabichromene, and cannabigerol, and of three terpenes, namely alpha-terpinene, bisabolol, and camphene, in an orally available pharmaceutical carrier, for the alleviation of the adverse effects of cancer chemotherapy agents, including adverse effects on the gastrointestinal tract, the chemoreceptor trigger zone, and the peripheral nervous system, and that shows activity adjunctively against ovarian cancer, particularly ovarian cancer that is therapeutically platinum-resistant or platinum-sensitive.
    Type: Application
    Filed: August 3, 2022
    Publication date: May 9, 2024
    Inventor: Patrick Moran
  • METHODS AND COMPOSITIONS FOR CANNABINOID-BASED THERAPEUTICS
    Publication number: 20240148760
    Abstract: The present disclosure provides methods and systems for forming a co-therapeutic composition. The co-therapeutic composition can comprise a cannabinoid compound and a non-cannabinoid therapeutic compound. The co-therapeutic composition can comprise a plurality of stable droplets as part of an emulsion. The co-therapeutic composition can be in other dosage forms, such as solid dosage forms (e.g., tablets).
    Type: Application
    Filed: May 26, 2023
    Publication date: May 9, 2024
    Inventor: William KLEIDON
  • Chelated Metal Oxide Cannabinoid Gel Composition
    Publication number: 20240148761
    Abstract: A homogeneous gel composition for topical wound treatment and other healthcare purposes. Said gel composition comprising a cationic chelated chitosan-silver gel incorporating at least one cannabinoid and having antimicrobial, antibacterial, anti-inflammatory and/or analgesic properties. A method for treating a wound or skin disorder using the gel composition is also disclosed.
    Type: Application
    Filed: November 3, 2023
    Publication date: May 9, 2024
    Inventor: William Wingfield
  • TOPICAL COMPOSITION CONTAINING CANNABINOIDS
    Publication number: 20240148762
    Abstract: A topical composition for skin ailments, conditions or diseases comprising lanolin or derivatives thereof, one or more extracted vegetable oils, one or more extracted plant oils, and one or more cannabinoids. The cannabinoids used in the topical composition may be selected cannabinoids such as CBD and/or analogs and derivatives, THC and/or analogs and derivatives, or mixtures thereof. The extracted vegetable oils and plant oils used in the topical composition may be squalane, meadowfoam seed oil, or a mixture thereof. These components used in the topical composition may be naturally derived from vegetables, plants, or animals. The topical composition has effective pharmacological activity to care for or treat skin ailments, conditions or diseases and may be used to care for or treat a human or an animal.
    Type: Application
    Filed: November 8, 2023
    Publication date: May 9, 2024
    Inventors: Francis G. Fanning, Tobias C. Ripsom, Marnie L. Peterson, William Onyebuagu
  • SIALIC ACID COMPOSITIONS FOR THE USE OF INHIBITING AND TREATING CORONAVIRUS INFECTION
    Publication number: 20240148763
    Abstract: The present invention relates to the use of compositions comprising sialic acid to inhibit or treat coronavirus infections, and in particular those caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2).
    Type: Application
    Filed: November 13, 2023
    Publication date: May 9, 2024
    Inventor: Jan Remmereit
  • INHIBITORS OF SGLT-1 AND USES THEREOF
    Publication number: 20240148764
    Abstract: This invention is in the field of medicinal pharmacology. In particular, the present invention relates to pharmaceutical agents which function as inhibitors of sodium-glucose cotransporter 1 (SGLT-1) activity. The invention further relates to methods of treating and/or ameliorating symptoms related to cystic fibrosis-related liver disease and diseases characterized with increased SGLT-1 activity, increased endoplasmic reticulum (ER) stress response, and/or increased hepatic inflammation.
    Type: Application
    Filed: March 4, 2022
    Publication date: May 9, 2024
    Inventors: Jie Xu, Kezhong Zhang, Xiubin Liang, Yuqing Eugene Chen
  • COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING THERAPY-RELATED CARDIOMYOPATHY ASSOCIATED WITH NEUTROPHIL INFILTRATION
    Publication number: 20240148765
    Abstract: Provided are methods for treating and/or preventing genotoxic stress-induced cardiac toxicity, which in some embodiments include administering to a subject an effective amount of an inhibitor of t-CH, of neutrophil activation, of neutrophil migration, or any combination thereof. In some embodiments, the genotoxic stress-induced cardiac toxicity results from exposure to one or more anti-tumor and/or anti-cancer therapies, including but not limited to treatment with one or more chemotherapeutics (e.g., doxorubicin) and/or treatment with radiation. In some embodiments, the genotoxic stress-induced cardiac toxicity, the chemotherapy-induced cardiac toxicity, the chemotherapy-induced heart damage, and/or the chemotherapy-induced reduction in cardiac function is characterized by a reduction in cardiac contractility, a thinning of a ventricular wall, a reduction in cardiomyocyte size, or any combination thereof.
    Type: Application
    Filed: March 14, 2022
    Publication date: May 9, 2024
    Applicant: University of Virginia Patent Foundation
    Inventors: Kenneth Walsh, Soichi Sano
  • Agent for Adjusting Hardness of Lens of Eye
    Publication number: 20240148766
    Abstract: An object of the present invention is to provide a novel agent for adjusting hardness of a lens of an eye which can be taken easily, conveniently, and safely for a long-term, can effectively adjust the hardness of the lens, and is capable of preventing, alleviating and improving poor focus and decreased near visual acuity, such as presbyopia, caused by aging and various diseases. The present invention solves the above object by providing an agent for adjusting hardness of a lens of an eye comprising a glycosyl hesperetin as an active ingredient.
    Type: Application
    Filed: November 15, 2021
    Publication date: May 9, 2024
    Inventors: Yosuke NAKAZAWA, Naoki MORISHITA, Shin ENDO, Masaki MIYAKE, Hitoshi MITSUZUMI, Motoshi HAYANO, Kazuo TSUBOTA
  • THE USE OF EMPAGLIFLOZIN FOR THE TREATMENT OF ULCERATIVE COLITIS AND CROHN'S DISEASE
    Publication number: 20240148767
    Abstract: A use of empagliflozin for the treatment of ulcerative colitis and Crohn's disease.
    Type: Application
    Filed: March 3, 2022
    Publication date: May 9, 2024
    Inventors: Jason DYCK, Karen Lynn MADSEN
  • Method of Preventing and Treating COVID-19 Infection
    Publication number: 20240148768
    Abstract: A method of treating an individual infected with COVID-19, the method comprising the steps of: providing an individual infected with COVID-19; and administering five antimicrobials to the individual, wherein the antimicrobials comprise: hydroxychloroquine; azithromycin; vitamin C; vitamin D; and zinc.
    Type: Application
    Filed: January 12, 2024
    Publication date: May 9, 2024
    Inventor: Sabine Hazan
  • PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CORONAVIRUS DISEASE 19, CONTAINING CARBOCYCLIC NUCLEOSIDE DERIVATIVE
    Publication number: 20240148769
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating coronavirus disease 19 (COVID-19) and specifically, to a pharmaceutical composition containing a carbocyclic nucleoside derivative represented by Chemical Formula A-1 or A-2 or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 17, 2022
    Publication date: May 9, 2024
    Applicant: FUTURE MEDICINE CO., LTD.
    Inventors: Hyuk Woo LEE, Seo Hyun SON, Ji Yoon KANG, Hyu Jeong JANG, Seong Wook SEO
  • ADVANTAGEOUS ANTI-HCV COMBINATION THERAPY
    Publication number: 20240148770
    Abstract: A synergistic pharmaceutical combination of Compound 1 or a pharmaceutically acceptable salt thereof (e.g.
    Type: Application
    Filed: December 14, 2023
    Publication date: May 9, 2024
    Applicant: Atea Pharmaceuticals, Inc.
    Inventors: Jean-Pierre Sommadossi, Adel Moussa, Keith M. Pietropaolo, Xiao-Jian Zhou
  • COMPOSITIONS AND METHODS FOR MODIFYING A PREDETERMINED TARGET NUCLEIC ACID SEQUENCE
    Publication number: 20240148771
    Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
    Type: Application
    Filed: May 15, 2023
    Publication date: May 9, 2024
    Applicant: TARGETGENE BIOTECHNOLOGIES LTD.
    Inventors: Yoel Moshe SHIBOLETH, Dan Michael WEINTHAL
  • METHODS AND COMPOSITIONS FOR TREATING A PREMATURE TERMINATION CODON-MEDIATED DISORDER
    Publication number: 20240148772
    Abstract: The invention relates generally to modified tRNAs and the use of modified tRNAs to express in a mammalian cell a functional gene product encoded by a gene containing a premature termination codon and/or to treat a disease mediated by a premature termination codon, e.g., Dravet syndrome.
    Type: Application
    Filed: October 30, 2020
    Publication date: May 9, 2024
    Inventors: Sean McFarland, Ying-Hsin Chen, Peter M. Eimon
  • PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20240148773
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Patatin-Like Phospholipase Domain Containing 3 (PNPLA3) gene, and methods of using such RNAi agents to inhibit expression of a PNPLA3 gene and methods of treating subjects having Nonalcoholic Fatty Liver Disease (NAFLD) and/or a PNPLA3-associated disorder.
    Type: Application
    Filed: June 1, 2023
    Publication date: May 9, 2024
    Inventors: Kevin Fitzgerald, Gregory Hinkle
  • Treatment Of Inflammation With Glucocorticoids And Angiopoietin-Like 7 (ANGPTL7) Inhibitors
    Publication number: 20240148774
    Abstract: The present disclosure provides methods of treating subjects having inflammation with an Angiopoietin-Like 7 (ANGPTL7) inhibitor and a glucocorticoid, methods of decreasing glucocorticoid-induced ophthalmic conditions in subjects, and methods of identifying subjects having an increased risk of developing glucocorticoid-induced ophthalmic conditions.
    Type: Application
    Filed: November 16, 2023
    Publication date: May 9, 2024
    Inventors: Gaurang Patel, Ying Hu, Kavita Praveen, Giovanni Coppola, Goncalo Abecasis, Aris Baras, Carmelo Romano
  • OLIGONUCLEOTIDE FOR INDUCING N-EXON SKIPPING DURING REST MRNA PRECURSOR PROCESSING
    Publication number: 20240148775
    Abstract: An oligonucleotide or a pharmacologically acceptable salt thereof according to the present invention contains a nucleotide sequence complementary to a continuous sequence of at least 12 bases in a target region constituted by a base sequence of SEQ ID No. 1, and induces N-exon skipping in human REST pre-mRNA processing. Such oligonucleotides are useful for manufacturing medicines for treatment of cancer, for example.
    Type: Application
    Filed: February 25, 2022
    Publication date: May 9, 2024
    Applicant: Osaka University
    Inventors: Masahito SHIMOJO, Satoshi OBIKA, Keishiro MISHIMA, Misa YOSHIDA
  • TUMESCENT SOLUTION WITH B VITAMINS
    Publication number: 20240148776
    Abstract: A tumescent solution including: a vasoconstrictor; a B vitamin and a pharmaceutically acceptable carrier. In some examples, the tumescent solution further includes a drug or therapeutic agent dissolved in the tumescent solution. Some examples relate to a method of subcutaneous delivery of a drug or therapeutic agent to a subject including subcutaneously administering to said subject a tumescent solution as disclosed herein. In some examples, infiltration of the tumescent solution achieves both prolonged local drug or therapeutic agent concentration within a tumescent subcutaneous tissue as well as a prolonged slow constant systemic absorption of drugs from the tumescent tissue into a systemic circulation. In some examples, the tumescent solution reduces neuropathic pain or the risk of developing neuropathic pain, treats a localized condition or reduces persistent postsurgical pain (PPP) in a subject.
    Type: Application
    Filed: November 3, 2023
    Publication date: May 9, 2024
    Inventors: Jeffrey Alan Klein, Paytra Alan Klein, Bram Alan Klein
  • METHODS AND COMPOSITIONS FOR TREATING CLOSTRIDIODES DIFFICILE INFECTIONS
    Publication number: 20240148777
    Abstract: Provided herein are immunogenic compositions for treating Clostridioides difficile infections.
    Type: Application
    Filed: September 28, 2023
    Publication date: May 9, 2024
    Inventors: Kevin P. KILLEEN, Ann THANAWASTIEN, Robert T. CARTEE, Michael W. FINN
  • GLYCOSIDE INHIBITORS OF YEAST
    Publication number: 20240148778
    Abstract: A composition of yeast polysaccharides including ?(1,6)-glucans, preferably also mannans and ?-glucans. The yeast polysaccharides are extracted from yeast cell wall fragments. Typically, the ?-glucans are ?(1,6)-glucans. Also, a method for obtaining such a composition, including at least one step of fractionating a composition of yeast cell walls and extracting an insoluble fraction, and at least one step of extracting a soluble fraction from the insoluble fraction obtained in step a). Further, a composition with a human or veterinary therapeutic objective, for the treatment of gastrointestinal pathologies associated with pathogenic microorganisms, as well as to its non-therapeutic use for improving intestinal comfort.
    Type: Application
    Filed: March 15, 2022
    Publication date: May 9, 2024
    Applicants: LESAFFRE ET COMPAGNIE, UNIVERSITÉ CLERMONT AUVERGNE, UNIVERSITE DE LILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS
    Inventors: Nathalie BALLET, Pascal VANDEKERCKOVE, Yann GUERARDEL, Shin-Yi YU, Adeline SIVIGNON, Nicolas BARNICH
  • METHODS FOR THE TREATMENT OF PROTEINOPATHIES
    Publication number: 20240148779
    Abstract: Provided is a method of i) preventing or reducing protein aggregation, ii) reducing protein deposition, iii) reducing cytotoxicity induced by protein aggregation or deposition or deposition, or iv) alleviating or reducing inflammation induced by protein aggregation or deposition in an individual, wherein the method comprises administering a therapeutically effective amount of a pharmaceutical composition including a gamma-cyclodextrin oligomer to the individual, thereby preventing or reducing protein aggregation, reducing protein deposition, reducing cytotoxicity induced by protein aggregation or deposition, or alleviating or reducing inflammation induced by protein aggregation or deposition in the individual diagnosed with, suspected to have, or at risk of developing proteinopathy.
    Type: Application
    Filed: October 10, 2023
    Publication date: May 9, 2024
    Applicant: RENATUS INC.
    Inventor: Hee Gon KIM
  • COMPOSITION AND USE OF AN OPHTHALMIC SOLUTION BASED ON HYALURONIC ACID AND ARABINOGALACTAN
    Publication number: 20240148780
    Abstract: An ophthalmic solution based on hyaluronic acid and arabinogalactan in synergistic amounts is used, alone or in combination with panthenol, vitamin E-D-?-polyethylene-glycol (TGPS) and trehalose, in the treatment of dry-eye syndrome, accompanied by the inflammatory phenomena related to the action of the enzyme system xanthine dehydrogenase/xanthine oxidase.
    Type: Application
    Filed: October 13, 2020
    Publication date: May 9, 2024
    Inventors: Domenico DE GRAZIA, Giulia DE GRAZIA, Francesco FARINELLI, Stefano REMIDDI, Ludovica SILVANI
  • RHAMNAN SULFATE-BASED THERAPEUTICS FOR NONALCOHOLIC FATTY LIVER DISEASE AND CIRCADIAN RHYTHM DISORDERS
    Publication number: 20240148781
    Abstract: The present invention describes compositions and methods for treatment of metabolic diseases and disorders, such as non-alcoholic fatty liver disease (NAFLD), and circadian rhythm-related disorders.
    Type: Application
    Filed: November 3, 2023
    Publication date: May 9, 2024
    Inventors: Aaron Baker, Nikita Patil